Civitas Therapeutics, Inc.

Pulmatrix, Inc.

Advanced Inhalation Research, Inc.

Pulmatrix Operating Company, Inc.

Alkermes, Inc.

Merz Pharmaceuticals Gmbh

Michael M Lipp

Richard P Batycky

Jean C Sung

Abhijit Kamerkar

Giovanni Caponetti

Jeffrey S Hrkach

Ernest D Penachio

Ralph W Niven

Kevin D Kee

David A Edwards

Elliot Ehrich

Jason Summa

Karen Fu

Mei-Ling Pan

Wen-I Li

Mariko Childs

Mark A Tracy

Charles D Blizzard

Kevin L Ward

Robert William Clarke

Martin Freed

Sujit K Basu

Katharina J Elbert

David L Hava

Rachel Ryznal

Daniel Leblanc

Rebecca Martin

Eliot Ehrich

Wen-I Ki

Richard Batycky

John Hanrahan

The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.

Methods for providing rapid relief of motor fluctuations in a Parkinson's disease patient

The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na), are small and dispersible.

Monovalent metal cation dry powders for inhalation

The invention provides stable, spray-dried, particle formulations containing a triptan, preferably sumatriptan, or a pharmaceutically acceptable salt thereof, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.

Triptan powders for pulmonary delivery

The invention relates to respirable dry particles that contain one or more divalent metal cations, such as magnesium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.

Cationic dry powders

The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 &#x3bc;m and a tap density of less than about 0.075 g/cm. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.

Ultra low density pulmonary powders

The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.

The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

Capsules containing high doses of levodopa for pulmonary use

The invention provides stable, spray-dried, particle formulations containing rapamycin, or pharmaceutically acceptable salts of rapamycin, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.

Rapamycin powders for pulmonary delivery

Particles having a tap density of less than 0.4 g/cminclude a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Use of simple amino acids to form porous particles

The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.

Dry powder formulations and methods for treating pulmonary diseases

Growing community of inventors

Framingham, MA, United States of America

Michael M Lipp